Safety and Efficacy Study of Co-transfering of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease

Inclusion Criteria

• •1. Clinically diagnosed as decompensated liver cirrhosis.
• •2. Hepatitis B/C Liver Cirrhosis After Viral Treatment, HBV/HCV Viral Loads Below Detection Level over six mouths, and the liver function remained below Child-pugh A grade or MELD score \>10.
• •3. Other causes of cirrhosis, liver function compensatory incomplete. In the past year, despite active medical treatment taken, the condition has continued to increase, at least because of cirrhosis complications such as ascites, spontaneous peritonitis, gastrointestinal bleeding, and hepatic encephalopathy in hospital over one time.
• •4. Need to intermittently supplement albumin and apply diuretic therapy.
• •5. Albumin \<35 g/L, total bilirubin \<170 umol/L, prothrombin activity\> 30%; (Prothrombin time \<20 s, moderate or lower mass ascites, spontaneous peritonitis and hepatic encephalopathy (grade II or lower), Child-pugh score\> 5 points).
• •6. There was no history of gastrointestinal hemorrhage within the last month and population with no high-risk portal hypertension and gastrointestinal bleeding was evaluated recently.
• •7. Unconditional acceptance of orthotopic liver transplantation.
• •8. Aged from 18 to 65 years.
• •9. Voluntarily signed informed consent form.